Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene
Hepatocellular carcinoma (HCC) is an aggressive and chemoresistant cancer type. The development of novel therapeutic strategies is still urgently needed. Personalized or precision medicine is a new trend in cancer therapy, which treats cancer patients with specific genetic alterations. In this study...
Guardado en:
Autores principales: | Jiunn-Chang Lin, Tsang-Pai Liu, Vivin Andriani, Muhammad Athoillah, Chih-Yang Wang, Pei-Ming Yang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a76810d2876f4db1b3065310518cb5d6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Magnetic nanoparticle hyperthermia potentiates paclitaxel activity in sensitive and resistant breast cancer cells
por: Rivera-Rodriguez A, et al.
Publicado: (2018) -
BMC bioinformatics
Publicado: (2000) -
Transcriptome-Based Identification of a Functional <i>Fasciola hepatica</i> Carboxylesterase B
por: Yaretzi J. Pedroza-Gómez, et al.
Publicado: (2021) -
Evolutionary bioinformatics online
Publicado: (2005) -
Journal of clinical bioinformatics
Publicado: (2011)